SCHEMBL1640658

SCHEMBL1640658

O=c1ccc(-c2ccc(CCO)cc2)n[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.66
LMNA P02545 3/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
CYP1A2 P05177 2/20 0.56
HRH3 Q9Y5N1 6/20 0.52
PDE3B Q13370 5/20 0.49
PDE3A Q14432 5/20 0.49
PDE4A P27815 3/20 0.45
PDE4B Q07343 3/20 0.45
PDE4C Q08493 3/20 0.45
PDE4D Q08499 3/20 0.45
JAK2 O60674 1/20 0.40
NTRK1 P04629 1/20 0.40
RET P07949 1/20 0.40
PDGFRB P09619 1/20 0.40
CDK8 P49336 1/20 0.40
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40
AURKB Q96GD4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10353474 0.83 MAPT (0.80) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL7302713 0.83 MAPT (0.66) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL3452908 0.82 LMNA (0.80) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL8114174 0.80 MAPT (0.74) MAPTLMNAMEN1KMT2ACYP1A2
Bromide SCHEMBL8108897 0.80 MAPT (0.69) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL25935974 0.79 MAPT (0.69) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL3109943 0.79 CYP1A2 (0.59) MAPTLMNAMEN1KMT2ACYP1A2
Bromide SCHEMBL8100497 0.78 MAPT (0.72) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL9815929 0.78 MAPT (0.97) MAPTLMNAMEN1KMT2ACYP1A2
SCHEMBL1639974 0.78 MAPT (0.59) MAPTLMNAMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328586-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS Cephalon, Inc. (US) 2011-06-08 EP disclosed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US disclosed
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-04-28 US disclosed
WO-2009142732-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-11-26 WO disclosed
WO-2009142732-A2 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098269-A1 Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 MAPT 2914/4885LMNA 4089/4885MEN1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.